Literature DB >> 18806155

MRI safety update 2008: part 1, MRI contrast agents and nephrogenic systemic fibrosis.

Frank G Shellock1, Alberto Spinazzi.   

Abstract

OBJECTIVE: This article is the first part of a two-part series on MRI safety. In this article, part 1, the topic of MRI contrast agents and nephrogenic systemic fibrosis (NSF) is addressed.
CONCLUSION: To prevent incidents and accidents associated with MRI, it is necessary to regularly revisit the safety topics that directly impact patient management especially with respect to the subjects that are "new" (e.g., MRI contrast agents and NSF), those that should be reassessed because of recent changes, topics that deserve emphasis because of controversy or confusion, and information that should be considered in light of new findings.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18806155     DOI: 10.2214/AJR.08.1038.1

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  38 in total

Review 1.  MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials.

Authors:  Frederik Barkhof; Jack H Simon; Franz Fazekas; Marco Rovaris; Ludwig Kappos; Nicola de Stefano; Chris H Polman; John Petkau; Ernst W Radue; Maria P Sormani; David K Li; Paul O'Connor; Xavier Montalban; David H Miller; Massimo Filippi
Journal:  Nat Rev Neurol       Date:  2011-12-06       Impact factor: 42.937

2.  Magnetic resonance angiography (MRA) of the calf station at 3.0 T: intraindividual comparison of non-enhanced ECG-gated flow-dependent MRA, continuous table movement MRA and time-resolved MRA.

Authors:  Stefan Haneder; Ulrike I Attenberger; Philipp Riffel; Thomas Henzler; Stefan O Schoenberg; Henrik J Michaely
Journal:  Eur Radiol       Date:  2011-01-28       Impact factor: 5.315

Review 3.  Management of incidental renal masses: Time to consider contrast-enhanced ultrasonography.

Authors:  Francesca Di Vece; Paola Tombesi; Francesca Ermili; Sergio Sartori
Journal:  Ultrasound       Date:  2016-01-14

4.  High relaxivity Gd(III)-DNA gold nanostars: investigation of shape effects on proton relaxation.

Authors:  Matthew W Rotz; Kayla S B Culver; Giacomo Parigi; Keith W MacRenaris; Claudio Luchinat; Teri W Odom; Thomas J Meade
Journal:  ACS Nano       Date:  2015-03-24       Impact factor: 15.881

Review 5.  Nephrogenic systemic fibrosis: a concise review for cardiologists.

Authors:  Benjamin Y C Cheong; Raja Muthupillai
Journal:  Tex Heart Inst J       Date:  2010

6.  Angiotensin-converting enzyme inhibitor-enhanced MR renography: repeated measures of GFR and RPF in hypertensive patients.

Authors:  Jeff L Zhang; Henry Rusinek; Louisa Bokacheva; Ruth P Lim; Qun Chen; Pippa Storey; Keyma Prince; Elizabeth M Hecht; Danny C Kim; Vivian S Lee
Journal:  Am J Physiol Renal Physiol       Date:  2009-01-21

7.  Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging--derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme.

Authors:  S J Mills; C Soh; C J Rose; S Cheung; S Zhao; G J M Parker; A Jackson
Journal:  AJNR Am J Neuroradiol       Date:  2009-10-22       Impact factor: 3.825

Review 8.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 9.  Biological effects and safety in magnetic resonance imaging: a review.

Authors:  Valentina Hartwig; Giulio Giovannetti; Nicola Vanello; Massimo Lombardi; Luigi Landini; Silvana Simi
Journal:  Int J Environ Res Public Health       Date:  2009-06-10       Impact factor: 3.390

10.  Recommendations for cardiovascular magnetic resonance in adults with congenital heart disease from the respective working groups of the European Society of Cardiology.

Authors:  Philip J Kilner; Tal Geva; Harald Kaemmerer; Pedro T Trindade; Juerg Schwitter; Gary D Webb
Journal:  Eur Heart J       Date:  2010-01-11       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.